替诺福韦酯联合双重免疫方案阻断HBV携带孕妇母婴病毒传播效果研究

doi:10.3969/j.issn.1672-5069.2021.03.007

摘要/Abstract

摘要： 目的观察应用替诺福韦酯联合双重免疫方案处理慢性乙型肝炎病毒(HBV)携带孕妇对母婴病毒传播阻断的效果。方法 2016年12月～2019年9月我院收治的HBV携带孕妇120例,采用随机数字表法分为对照组60例和观察组60例。对照组孕妇未进行抗病毒治疗,观察组孕妇在孕26～28个月时开始口服替诺福韦酯,治疗至分娩。所有新生儿出生后立即接种乙肝疫苗和乙型肝炎免疫球蛋白进行双重免疫。采用聚合酶链式反应法检测血清HBV DNA,采用胶体金法检测血清HBsAg和HBeAg。结果在分娩时,观察组血清ALT水平为(23.2±3.6)IU/L,与对照组【(26.9±4.0)IU/L,P>0.05】比,无显著性差异,血清HBV DNA载量为(3.1±0.7) lg copies/mL,显著低于对照组【(5.9±0.8)lg copies/mL,P<0.05】;观察组新生儿Apgar评分为(9.7±0.3)分,与对照组【(9.9±0.5)分,P>0.05】比,无显著性差异,两组新生儿身高、体质量和头围比较,无显著性差异(P>0.05);在分娩时、出生后6个月和12个月,观察组婴儿HBV感染率为1.7%、1.7%和1.7%,与对照组(分别为11.7%、11.7%和13.3%,P>0.05)比,无显著性差异。结论应用替诺福韦酯联合双重免疫方案处理HBV携带孕妇及其新生儿能显著降低孕妇血清HBV载量,可能降低婴儿HBV感染率,值得进一步扩大观察。

关键词: 乙型肝炎病毒携带者, 替诺福韦酯, 乙肝疫苗, 乙型肝炎免疫球蛋白, 母婴传播, 孕妇, 阻断

Abstract: Objective The purpose of this study was to observe the efficacy of tenofovir disoproxil fumarate and dual immunization regimen in blocking mother-to-child hepatitis B viral transmission in pregnant women with hepatitis B virus (HBV) carrier.Methods 120 HBV carrying pregnant women were admitted to our hospital between December 2016 and September 2019,and were randomly divided into control and observation group. The pregnant women in the control group didn’t receive any antiviral treatment, while those in the observation group were treated with tenofovir disoproxil fumarate at gestational week 26 to 28 until delivery. The newborns were inoculated with dual immunization regimen, e.g. hepatitis B vaccine and hepatitis B immunoglobulin immediately after birth. Serum HBV DNA loads were detected by PCR, and serum HBsAg and HBeAg were assayed by colloidal gold method.Results At delivery, serum ALT level in the observation women was (23.2±3.6)IU/L, not significantly different compared to [(26.9±4.0)IU/L, P>0.05] in the control, serum HBV DNA loads was (3.1±0.7) lg copies/mL, significantly lower than [(5.9±0.8) lg copies/mL, P<0.05] in the control; the Apgar score in the observation new infants was (9.7±0.3), not significantly different compared to [(9.9±0.5), P>0.05] in the control, and the lengths, body masses and head circumferences in the two group newborns were not significantly different (P>0.05); at delivery, six months and twelve months after delivery, the positive HBV infection in the observation infants were 1.7%, 1.7% and 1.7%, not significantly lower than 11.7%, 11.7% and 13.3% (P>0.05) in the control.Conclusion The management of pregnant women with HBV carrier with oral tenofovir disoproxil fumarate and double immunization program in time for newborns could significantly reduce serum HBV loads, and therefore might decrease mother to infant HBV transmission, which needs multi-center investigation.

Key words: Hepatitis B viral carrier, Tenofovir disoproxil fumarate, Dual immunization regimen, Mother-to-child transmission, Blocking

黄永群, 黄润强, 熊平安. 替诺福韦酯联合双重免疫方案阻断HBV携带孕妇母婴病毒传播效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 331-334.

Huang Yongqun, Huang Runqiang, Xiong Ping’an. Efficacy of tenofovir disoproxil fumarate and dual immunization regimen in blocking mother-to-child hepatitis B viral transmission in pregnant women with hepatitis B virus carrier[J]. Journal of Practical Hepatology, 2021, 24(3): 331-334.

参考文献

[1] Terrault N A, Bzowej N H, Chang K M, et al. Aasld guidelines for treatment of chronic hepatitisB. Hepatology, 2016, 63(1): 261-283.
[2]Brown R J, Mcmahon B J, Lok A S, et al. Antiviral therapy in chronic hepatitisB viral infection during pregnancy: a systematic review and meta-analysis. Hepatology, 2016, 63(1): 319-333.
[3] Yi P, Chen R, Huang Y, et al. Management of mother-to-child transmission of hepatitisB virus: propositions and challenges. J Clin Virol, 2016, 77(8): 32-39.
[4] 马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析. 实用肝脏病杂志, 2019, 22(6): 836-839.
[5] 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志, 2016, 19(3): 389-400.
[6] 王垒, 范林, 彭贵主, 等. 乙型肝炎免疫球蛋白在肝移植术后乙型肝炎复发防治中的应用. 中华肝胆外科杂志, 2017, 23(7): 494-498.
[7] Eke A C, Eleje G U, Eke U A, et al. HepatitisB immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database Syst Rev, 2017, 2(6): 8545-8545.
[8] Paul R C, Rahman M, Wiesen E, et al. HepatitisB surface antigen seroprevalence among prevaccine and vaccine era children in Bangladesh. Am J Trop Med Hyg, 2018, 99(3): 764-771.
[9] Mccormick C A, Mccormick P A. Prevention of mother-to-child transmission in patients with chronic hepatitisB virus infection and high viral loads. Iran Med J, 2018, 111(10): 831-831.
[10] 陈欣, 陈立冬, 李庭红.替诺福韦酯治疗多重耐药的乙型肝炎肝硬化患者疗效初步研究. 实用肝脏病杂志, 2018, 21(5): 681-684.
[11] Agarwal K, Brunetto M, Seto W K, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68(4): 672-681.
[12] Chen J Z, Liao Z W, Huang F L, et al. Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitisB in pregnancies with high viral load. Sci Rep, 2017, 7(1): 4132-4132.
[13] Chan H L, Fung S, Seto W K, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195.
[14] Buti M, Gane E, Seto W K, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1(3): 196-206.
[15] Wang M, Bian Q, Zhu Y, et al. Real-world study of tenofovir disoproxil fumarate to prevent hepatitisB transmission in mothers with high viral load. Aliment Pharmacol Ther, 2019, 49(2): 211-217.
[16] Zeng J, Zheng C, Li H.Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy. Medicine (Baltimore), 2019, 98(14): 15092-15092.
[17] Nakano L A, Katayose J T, Abreu R M, et al. Assessment of the prevalence of vertical hepatitisB transmission in two consecutive generations. Rev Assoc Med Bras, 2018, 64(2): 154-158.
[18] Weis N, Cowan S, Hallager S, et al. Vertical transmission of hepatitisB virus during pregnancy and delivery in Denmark. Scand J Gastroenterol, 2017, 52(2): 178-184.
[19] Dionne-Odom J, Njei B, Tita A. Elimination of vertical transmission of hepatitisB in Africa: a review of available tools and new opportunities. Clin Ther, 2018, 40(8): 1255-1267.
[20] Sun W, Zhao S, Ma L, et al. Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. BMC Gastroenterol, 2017, 17(1): 51-51.
[21] 毛创杰, 胡蓉, 曾义岚, 等.替诺福韦酯对四川地区妊娠中期高HBV载量慢性乙型肝炎母婴阻断的疗效 . 中华实验和临床感染病杂志(电子版), 2019, 13(6): 485-490.